Format

Send to

Choose Destination
Low Urin Tract Symptoms. 2015 May;7(2):84-92. doi: 10.1111/luts.12053. Epub 2014 Mar 11.

Efficacy and Safety of the Selective β3 -Adrenoceptor Agonist Mirabegron in Japanese Patients with Overactive Bladder: A Randomized, Double-Blind, Placebo-Controlled, Dose-Finding Study.

Author information

1
Division of Bioengineering and LUTD Research, School of Engineering, Nihon University, Koriyama, Japan.
2
Department of Human Arts Sciences, University and Graduate School of Human Arts Sciences, Saitama, Japan.
3
Department of Continence Medicine, The University of Tokyo Graduate School of Medicine, Tokyo, Japan.
4
Department of Urology, University of Yamanashi, Yamanashi, Japan.
5
Department of Urology, Shinshu University, Matsumoto, Japan.
6
Astellas Pharma Inc, Tokyo, Japan.

Abstract

OBJECTIVES:

To evaluate the efficacy and safety of the β3 -adrenoceptor agonist, mirabegron, compared with placebo in Japanese patients with overactive bladder (OAB).

METHODS:

Patients with OAB symptoms for ≥24 weeks, ≥8 micturitions/24 h on average, and ≥1 episode of urgency and/or urgency incontinence/24 h were randomized to mirabegron (25, 50 or 100 mg) or placebo for 12 weeks. The primary endpoint was change from baseline to end of study in the mean number of micturitions/24 h. Secondary endpoints included micturition variables related to urgency, incontinence, volume voided, and quality of life based on the King's Health Questionnaire (KHQ). Safety was evaluated based on adverse events (AEs), laboratory findings, vital signs, electrocardiogram, and post-void residual volume.

RESULTS:

In total, 842 patients were randomized to placebo (n = 214), mirabegron 25 mg (n = 211), 50 mg (n = 208), or 100 mg (n = 209). The primary endpoint was significantly improved in each mirabegron group compared with placebo (P < 0.001; Williams' multiple comparison test). The maximal efficacy in the primary endpoint was observed at the 50 mg dose. Significant improvements were also observed in incontinence, urgency incontinence, mean volume voided, and 3 of the 9 domains from the KHQ (incontinence impact, physical limitations, and severity measures) at each mirabegron dose. Urgency episodes decreased, and mean volume voided increased, dose-dependently. The incidence of AEs in each mirabegron dose was comparable with placebo.

CONCLUSIONS:

Mirabegron demonstrated significant improvements in OAB symptoms compared with placebo and was well tolerated.

TRIAL REGISTRATION:

ClinicalTrials.gov NCT00527033.

KEYWORDS:

dose-response; efficacy; mirabegron; overactive bladder; safety

PMID:
26663687
DOI:
10.1111/luts.12053
[Indexed for MEDLINE]

Supplemental Content

Loading ...
Support Center